source
- Merck's $1.3B EyeBio investment yields first ophthalmology successMerck's strategic move to re-enter ophthalmology has begun to show results after its 2024 acquisition of EyeBio. The company committed $1.3 billion upfront for EyeBio, aiming to broaden its pipeli…
- Kyverna reports positive one-year CAR-T results for rare stiff person syndrome, supporting FDA filingKyverna Therapeutics announced that its CAR-T therapy for stiff person syndrome showed positive results after one year of treatment. The trial involved patients with the rare autoimmune disorder,…